Table 3.
Hematological factors of study groups.
| Study groups | Hematological factors | ||||||
|---|---|---|---|---|---|---|---|
| WBC, × 103/µL | RBC, × 106/µL | Hb, g/dL | Plt, × 103/µL | AST/ALT ratio | LDH, IU/L | CKMB, IU/L | |
| Control | 9.75 ± 2.24 | 7.10 ± 0.83 | 13.97 ± 1.14 | 643.83 ± 202.03 | 1.74 ± 0.42 | 1853.17 ± 728.11 | 68.67 ± 30.79 |
| 5-FU | 8.16 ± 3.49 | 4.27 ± 0.59*** | 9.98 ± 2.43** | 628.60 ± 258.47 | 3.71 ± 0.31**** | 2541.40 ± 544.56 | 102.60 ± 14.99 |
| 5-FU + Pro | 22.48 ± 14.05# | 5.24 ± 0.58** | 11.10 ± 0.91* | 1353.83 ± 249.26***, ### | 2.89 ± 0.52**, #, $ | 2754.50 ± 771.68 | 105.50 ± 61.26 |
| 5-FU + CLC | 11.53 ± 3.93 | 6.22 ± 1.26# | 10.63 ± 0.77* | 932.50 ± 297.09 | 2.13 ± 0.48###, $ | 1780.80 ± 460.55 | 53.00 ± 12.02 |
Values are expressed as mean ± standard deviation (SD). Groups: Control, Normal saline; 5-FU, 5-FU 125 mg/kg; 5-FU + Pro, 5-FU 125 mg/kg + Propolis ethanolic extract 250 mg/kg/d; 5-FU + CLC, 5-FU 125 mg/kg + Colchicine 5 mg/kg/d. *, **, ***, and **** Indicate statistically significant difference compared to the control group (p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively). #, and ### Indicate statistically significant difference compared to the 5-FU group (p < 0.05, and p < 0.001, respectively). $ Indicate statistically significant difference between the treatment groups (p < 0.05).